Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content
CDC EID journal Volume 14 Number 2—February 2008 Main Article

Volume 14, Number 2—February 2008

Research

Cost-effectiveness of Human Papillomavirus Vaccination in the United States

Harrell W. Chesson*Comments to Author , Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
Author affiliations: *Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

Main Article

Table 1

Estimated cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in the United States*

Parameter Population model
 Cohort model;
no herd immunity, $US
No herd immunity, $US Herd immunity, $US
Excluding anal, vaginal, vulvar, and oropharyngeal cancers
Vaccine targets HPV types 6,11,16,18 10,294 5,336 8,593
Vaccine targets HPV types 16,18
 14,723
 10,318
 12,562
Including anal, vaginal, vulvar, and orophayngeal cancers†
Vaccine targets HPV types 6,11,16,18 8,137 3,906 6,430
Vaccine targets HPV types 16,18 11,602 7,848 9,471

*When applying base-case parameter values to 12 model variations. QALY, quality-adjusted life year; HPV, human papillomavirus.
†The oropharyngeal cancer sites we included were base of tongue, tonsillar, and other sites as described in the Technical Appendix.

Main Article

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
TOP